Weight-loss drug for sleep apnea without CPAP
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.
This study tests a new weight-loss medication called maridebart cafraglutide against a placebo in people with moderate to severe obstructive sleep apnea who are not using a CPAP machine. The goal is to find out if weight loss can reduce symptoms like pauses in breathing during sleep.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a sleep study (polysomnography) showing an apnea-hypopnea index (AHI) of 15 or higher.
- You have a body mass index (BMI) of 27 or more.
- You have tried to lose weight through diet and exercise but have not been successful.
- You have not used a CPAP machine for at least 4 weeks, and you do not plan to use it during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a new medicine, called Maridebart Cafraglutide, can help people with obstructive sleep apnea who are already using a CPAP machine. The medicine may help with weight loss and potentially improve sleep apnea. Participants will either receive the medicine or a placebo (an inactive substance), and the study lasts for several months.
This study tests whether a new injectable medicine called NNC0487-0111 helps people with excess weight and moderate-to-severe obstructive sleep apnea (a condition where breathing stops repeatedly during sleep) lose weight and improve their sleep apnea—without needing a CPAP machine. The goal is to see if better weight loss can reduce sleep apnea symptoms.
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
This trial tests a new medication (maridebart cafraglutide) to see if it can reduce fat in the liver and help with weight loss. It may be an option for adults with excess liver fat and obesity or overweight who haven't been able to lose weight with diet and exercise alone.
Hear when a new Obstructive Sleep Apnea trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.